These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

893 related articles for article (PubMed ID: 13130479)

  • 21. Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts.
    Brembilla NC; Montanari E; Truchetet ME; Raschi E; Meroni P; Chizzolini C
    Arthritis Res Ther; 2013 Oct; 15(5):R151. PubMed ID: 24289089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis.
    Chizzolini C; Raschi E; Rezzonico R; Testoni C; Mallone R; Gabrielli A; Facchini A; Del Papa N; Borghi MO; Dayer JM; Meroni PL
    Arthritis Rheum; 2002 Jun; 46(6):1602-13. PubMed ID: 12115192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effector function of type II collagen-stimulated T cells from rheumatoid arthritis patients: cross-talk between T cells and synovial fibroblasts.
    Cho ML; Yoon CH; Hwang SY; Park MK; Min SY; Lee SH; Park SH; Kim HY
    Arthritis Rheum; 2004 Mar; 50(3):776-84. PubMed ID: 15022319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased levels of transforming growth factor beta receptor type I and up-regulation of matrix gene program: A model of scleroderma.
    Pannu J; Gardner H; Shearstone JR; Smith E; Trojanowska M
    Arthritis Rheum; 2006 Sep; 54(9):3011-21. PubMed ID: 16947635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential regulation of metalloproteinase production, proliferation and chemotaxis of human lung fibroblasts by PDGF, interleukin-1beta and TNF-alpha.
    Sasaki M; Kashima M; Ito T; Watanabe A; Izumiyama N; Sano M; Kagaya M; Shioya T; Miura M
    Mediators Inflamm; 2000; 9(3-4):155-60. PubMed ID: 11132772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of osteonectin, decorin, and transforming growth factor-beta 1 genes in fibroblasts cultured from patients with systemic sclerosis and morphea.
    Vuorio T; Kähäri VM; Black C; Vuorio E
    J Rheumatol; 1991 Feb; 18(2):247-51. PubMed ID: 2023219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Failure of catecholamines to shift T-cell cytokine responses toward a Th2 profile in patients with rheumatoid arthritis.
    Wahle M; Hanefeld G; Brunn S; Straub RH; Wagner U; Krause A; Häntzschel H; Baerwald CG
    Arthritis Res Ther; 2006; 8(5):R138. PubMed ID: 16889669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced interleukin 6 production by cultured fibroblasts from patients with systemic sclerosis in response to platelet derived growth factor.
    Takemura H; Suzuki H; Fujisawa H; Yuhara T; Akama T; Yamane K; Kashiwagi H
    J Rheumatol; 1998 Aug; 25(8):1534-9. PubMed ID: 9712097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis.
    Distler JH; Jüngel A; Pileckyte M; Zwerina J; Michel BA; Gay RE; Kowal-Bielecka O; Matucci-Cerinic M; Schett G; Marti HH; Gay S; Distler O
    Arthritis Rheum; 2007 Dec; 56(12):4203-15. PubMed ID: 18050252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-1beta and macrophage migration inhibitory factor (MIF) in dermal fibroblasts mediate UVA-induced matrix metalloproteinase-1 expression.
    Honda A; Abe R; Makino T; Norisugi O; Fujita Y; Watanabe H; Nishihira J; Iwakura Y; Yamagishi S; Shimizu H; Shimizu T
    J Dermatol Sci; 2008 Jan; 49(1):63-72. PubMed ID: 18060744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In situ expression and serum levels of tumor necrosis factor-alpha receptors in patients with early stages of systemic sclerosis.
    Gruschwitz MS; Albrecht M; Vieth G; Haustein UF
    J Rheumatol; 1997 Oct; 24(10):1936-43. PubMed ID: 9330935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis.
    Reich N; Maurer B; Akhmetshina A; Venalis P; Dees C; Zerr P; Palumbo K; Zwerina J; Nevskaya T; Gay S; Distler O; Schett G; Distler JH
    Arthritis Rheum; 2010 Jan; 62(1):280-90. PubMed ID: 20039427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T cells which do not express membrane tumor necrosis factor-alpha activate macrophage effector function by cell contact-dependent signaling of macrophage tumor necrosis factor-alpha production.
    Suttles J; Miller RW; Tao X; Stout RD
    Eur J Immunol; 1994 Aug; 24(8):1736-42. PubMed ID: 8056032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse.
    Ong VH; Evans LA; Shiwen X; Fisher IB; Rajkumar V; Abraham DJ; Black CM; Denton CP
    Arthritis Rheum; 2003 Jul; 48(7):1979-91. PubMed ID: 12847692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pathogenesis of systemic scleroderma: immunological aspects].
    Mouthon L; García De La Peña-Lefebvre P; Chanseaud Y; Tamby MC; Boissier MC; Guillevin L
    Ann Med Interne (Paris); 2002 May; 153(3):167-78. PubMed ID: 12218899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated matrix metalloproteinase-9 in patients with systemic sclerosis.
    Kim WU; Min SY; Cho ML; Hong KH; Shin YJ; Park SH; Cho CS
    Arthritis Res Ther; 2005; 7(1):R71-9. PubMed ID: 15642145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate.
    Dooley A; Shi-Wen X; Aden N; Tranah T; Desai N; Denton CP; Abraham DJ; Bruckdorfer R
    Rheumatology (Oxford); 2010 Nov; 49(11):2024-36. PubMed ID: 20627968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic exposure of interleukin-13 suppress the induction of matrix metalloproteinase-1 by tumour necrosis factor α in normal and scleroderma dermal fibroblasts through protein kinase B/Akt.
    Brown Lobbins ML; Shivakumar BR; Postlethwaite AE; Hasty KA
    Clin Exp Immunol; 2018 Jan; 191(1):84-95. PubMed ID: 28884475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of hepatocyte growth factor and its receptor (c-met) in skin fibroblasts from patients with systemic sclerosis.
    Kawaguchi Y; Harigai M; Hara M; Fukasawa C; Takagi K; Tanaka M; Tanaka E; Nishimagi E; Kamatani N
    J Rheumatol; 2002 Sep; 29(9):1877-83. PubMed ID: 12233882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.